Kane Biotech Unveils Clinical Findings on revyve® at SAWC Conference

Kane Biotech Inc., based in Winnipeg, Manitoba, has announced that its Interim Chief Executive Officer, Dr. Robert Huizinga, will present clinical data on its innovative revyve® product line at the Symposium on Advanced Wound Care (SAWC) Fall conference. This event is scheduled to take place from September 3-6, 2025, in Las Vegas, Nevada. The presented data indicates promising results for wound healing in complex cases, particularly those that have persisted for over two years.

The SAWC conference serves as a platform for multidisciplinary professionals in the field of wound care, including physicians, nurses, podiatrists, and researchers. Attendees share the latest evidence-based practices and clinical innovations aimed at enhancing outcomes in wound management. During the conference, Kane Biotech will showcase two significant presentations that demonstrate the efficacy of its revyve Antimicrobial Wound Gel.

The first presentation focuses on the clinical use of revyve in treating a two-year-old non-healing Stage 4 sacral ulcer in an elderly patient. Previous treatments had included daily dressing changes with silver-based antimicrobial agents. The introduction of revyve resulted in a remarkable reduction in pain, dropping from a score of 10/10 to 0 within three weeks. Additionally, the size of the wound decreased significantly, alongside a noted reduction in Klebsiella pneumonia cultures during treatment.

The second presentation highlights the use of revyve in conjunction with a vibrational debridement tool for an elderly female patient suffering from a two-year-old non-healing venous leg ulcer. Initially presenting with slough, eschar, and necrotic tissue, the wound’s pain level was assessed at 5/10. Following treatment with revyve, the patient’s pain resolved completely by Week three, and the wound demonstrated a 60% reduction in size over eight weeks, alongside decreased discharge.

Kane’s products, including the revyve Antimicrobial Wound Gel and the revyve Antimicrobial Wound Gel Spray, have received FDA 510(k) clearance and are also approved by Health Canada. The company aims to disrupt biofilms that contribute to antibiotic resistance in wounds, which can lead to serious clinical complications and increased healthcare costs.

Dr. Huizinga is expected to meet with potential U.S. distributors during the conference, furthering Kane Biotech’s outreach in the wound care market. The company is committed to developing novel treatments that enhance healing outcomes and improve patient quality of life.

For additional details on the revyve product line, interested individuals may visit the official websites at revyvegel.com or revyvegel.ca.

Kane Biotech Inc. continues to lead in the development of advanced wound care solutions, addressing critical needs in healthcare. As the company progresses, it remains focused on innovation and impactful clinical results that benefit patients worldwide.

For inquiries, please contact:
Dr. Robert Huizinga
Interim CEO
Kane Biotech Inc.
Email: [email protected]
Phone: (780) 970-1100

Ray Dupuis
Chief Financial Officer
Email: [email protected]
Phone: (204) 298-2200

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.